Arman Esfandiari Selected Research

Hypoxia (Hypoxemia)

2/2018

MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Arman Esfandiari Research Topics

Disease

2	Neoplasms (Cancer) 01/2023 - 02/2018
2	Melanoma (Melanoma, Malignant) 12/2018 - 01/2018
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2023
1	Lymphoma (Lymphomas) 01/2023
1	Neuroblastoma 03/2018
1	Ovarian Neoplasms (Ovarian Cancer) 02/2018
1	Pancreatic Neoplasms (Pancreatic Cancer) 02/2018
1	Hypoxia (Hypoxemia) 02/2018

Drug/Important Bio-Agent (IBA)

3	RG7388IBA 12/2018 - 01/2018
2	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 02/2018
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2018 - 02/2018
2	nutlin 3IBA 12/2018 - 01/2018
2	siremadlinIBA 12/2018 - 01/2018
1	IminesIBA 01/2023
1	Immunoconjugates (Immunoconjugate)IBA 01/2023
1	pyrrolo(2,1-c)(1,4)benzodiazepineIBA 01/2023
1	loncastuximab tesirineIBA 01/2023
1	trametinibIBA 12/2018
1	Adenosine Diphosphate Ribose (ADP-Ribose)IBA 02/2018
1	Adenosine Diphosphate (ADP)IBA 02/2018
1	ProdrugsIBA 02/2018
1	olaparibIBA 02/2018
1	N- (2,3- dihydroxypropyl)- 1- ((2- fluoro- 4- iodophenyl)amino)isonicotinamideIBA 02/2018
1	TH 302IBA 02/2018
1	GSK2830371IBA 01/2018

Therapy/Procedure

2	Therapeutics 03/2018 - 02/2018
1	Immunotherapy 03/2018